BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.4, pp.409-412, 2014 (SCI-Expanded)
Background: The beneficial effects of bevacizumab, a widely used agent in metastatic colorectal cancer (mCRC), on clinical survival have been proven. This study investigated the correlation of the clinical benefits and prognosis with proteinuria and other parameters.